SMS Pharma Q1 FY27 Results: Profit Rs 21.13 Cr, MD Re-appointed, Rs 50 Cr Loan to Subsidiary
SMS Pharmaceuticals Limited reported Q1 FY27 results with a net profit of ₹21.13 crore (standalone) and ₹20.91 crore (consolidated). The Board approved the re-appointment of Mr. Ramesh Babu Potluri as CMD for five years from Oct 1, 2026. A loan of up to ₹50 crore will be given to subsidiary SMS Peptides. The 38th AGM is on Sept 23, 2026.
The re-appointment of the MD and the loan to the subsidiary are significant corporate actions that could impact future operations and financial structure.
The company reported improved financial results and the re-appointment of a key management person, indicating stability and continued leadership.
SMS Pharmaceuticals Limited announced its financial results for the first quarter ended June 30, 2026, on July 31, 2026. The company's Board of Directors approved the un-audited standalone and consolidated financial results for the quarter.
The company reported a net profit after tax of ₹2,113.26 lakhs (₹21.13 crore) for the standalone results and ₹2,090.90 lakhs (₹20.91 crore) for the consolidated results for the first quarter ended June 30, 2026.
In addition to the financial results, the Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for a term of five years, effective from October 1, 2026, to September 30, 2031, subject to shareholder approval.
Furthermore, the Board approved a loan of up to ₹50 crore to its subsidiary, SMS Peptides Private Limited, in one or more tranches, subject to shareholder approval.
The 38th Annual General Meeting (AGM) is scheduled for Wednesday, September 23, 2026. The Register of Members and Share Transfer Books will be closed from September 17, 2026, to September 23, 2026, for the AGM. The record date for determining eligibility for dividend for FY 2025-26 has been fixed as September 16, 2026.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.